+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Infectious Diseases in-Vitro Diagnostics Market by Test Type, Technology, Pathogen, End User, Application - Global Forecast to 2030- Product Image
Infectious Diseases in-Vitro Diagnostics Market by Test Type, Technology, Pathogen, End User, Application - Global Forecast to 2030- Product Image
Sale

Infectious Diseases in-Vitro Diagnostics Market by Test Type, Technology, Pathogen, End User, Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5337418
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Infectious Diseases In-Vitro Diagnostics Market grew from USD 52.51 billion in 2024 to USD 56.40 billion in 2025. It is expected to continue growing at a CAGR of 7.26%, reaching USD 80.00 billion by 2030.

Navigating a New Era of Infectious Disease Diagnostics

The infectious diseases in-vitro diagnostics arena has never been more critical or dynamic. Recent years have underscored the vital role of accurate, rapid, and accessible testing in mitigating outbreaks, guiding clinical decisions, and strengthening global health security. As microbial threats evolve and antimicrobial resistance accelerates, laboratories and healthcare providers demand precise tools that can identify pathogens swiftly while offering robust epidemiological insights. Moreover, the integration of molecular techniques alongside traditional culture methods has redefined diagnostic workflows, enabling earlier interventions and more informed treatment plans.

Against this backdrop, stakeholders across the value chain face mounting pressure to innovate under cost constraints, regulatory complexity, and supply chain uncertainties. The convergence of digital health platforms, point-of-care solutions, and advanced data analytics signals a paradigm shift in how diagnostics will be developed, commercialized, and deployed. Strategic investments now will determine which organizations lead in shaping tomorrow’s standard of care. This executive summary presents a comprehensive examination of the transformational forces at play, equipping decision-makers with the contextual intelligence needed to navigate the evolving infectious diseases in-vitro diagnostics market with confidence.

Rewriting Diagnostic Paradigms Through Technology and Data

Diagnostic technologies are undergoing a metamorphosis driven by rapid innovation, growing data integration, and shifting clinical priorities. High-throughput molecular platforms, including next-generation sequencing and isothermal amplification methods, are enabling unprecedented accuracy and throughput, while point-of-care devices are bringing laboratory-grade testing closer to patients and remote settings. The proliferation of artificial intelligence and machine learning tools has begun to augment result interpretation, enabling predictive insights and workflow optimization at scale.

Regulatory landscapes are also evolving to accommodate accelerated approvals for emergency use and breakthrough diagnostics, creating new pathways for rapid commercialization. Simultaneously, manufacturers are pursuing modular designs that allow seamless expansion of test menus, enhancing flexibility amid emerging pathogen threats. The digital transformation extends beyond the instrument, with cloud-enabled data repositories and interoperable informatics ecosystems enabling real-time surveillance and decision support. Together, these transformative shifts are redefining value propositions across the diagnostics continuum, from reagent development and instrument design to sample management and result dissemination.

Adapting to New Trade Dynamics and Procurement Realities

The imposition of additional tariffs on select imported diagnostic reagents and instruments in 2025 has introduced a new layer of complexity for market participants. Cost pressures are rising for manufacturers that rely on specialized raw materials and high-precision components sourced globally. These increased duties have the potential to inflate reagent prices, dampen profit margins, and compel end-users to reassess procurement strategies. In turn, laboratories and healthcare systems are seeking alternative sourcing arrangements or negotiating new supply agreements to mitigate tariff-induced cost escalations.

To respond, many vendors are accelerating localization efforts by establishing manufacturing capabilities closer to primary markets and diversifying their supplier networks. Strategic alliances with domestic producers of consumables and intermediates have emerged as a key mechanism to stabilize input costs. At the same time, companies are exploring value-based contracting models that align pricing with clinical outcomes, thereby offsetting price sensitivities. Although short-term disruptions may linger, the pragmatic adjustments and collaborative initiatives underway suggest that the market will adapt, preserving innovation momentum and sustaining patient access to critical diagnostics.

Unveiling Market Dynamics Across Test Types and Applications

When the market is examined through the lens of test type, culture methods encompass both automated and manual modalities that continue to serve as gold standards for pathogen isolation, while the surge in molecular diagnostics leverages loop mediated isothermal amplification, next generation sequencing, and polymerase chain reaction to deliver heightened sensitivity and turnaround speed. Rapid tests provide critical triage capabilities in decentralized settings, and serology platforms employing chemiluminescence immunoassay, enzyme linked immunosorbent assay, and lateral flow formats facilitate antibody surveillance and post-infection assessments.

A technology-centric view reveals that immunoassay systems maintain strong presence in high-volume settings, mass spectrometry is gaining traction for specialized pathogen identification, microarrays offer multiplexing advantages, polymerase chain reaction remains a cornerstone for targeted detection, and sequencing technologies propel comprehensive genomic surveillance. Pathogen segmentation underscores the dominance of bacterial assays-particularly those targeting Enterobacteriaceae, Mycobacterium tuberculosis, and Staphylococcus aureus-alongside viral detection workflows designed around hepatitis virus, human immunodeficiency virus, and influenza virus panels, with emerging fungal and parasitic applications expanding diagnostic portfolios.

End-user analysis highlights that academic research institutions drive innovation and validation workstreams, clinics and hospitals-both private and public-constitute the primary volume channels, and specialized clinical and reference laboratories deliver high-complexity testing services. Finally, the application perspective aligns with core objectives in diagnosis, epidemiological surveillance, patient monitoring, and population screening, reflecting an integrated approach to disease management and public health.

Regional Growth Patterns and Market Maturation Trends

The Americas continue to anchor global demand for infectious diseases diagnostics, propelled by extensive healthcare infrastructure, significant public health investments, and a strong emphasis on pandemic preparedness. The U.S. market, in particular, leads in the adoption of advanced molecular assays and point-of-care solutions, while Latin American nations are bolstering domestic testing capacity to improve outbreak response and surveillance.

Across Europe, Middle East & Africa, regulatory harmonization efforts within the European Union streamline market entry for innovative assays, though fragmented reimbursement landscapes and economic disparities pose adoption challenges. In the Middle East and Africa, growing public-private partnerships and targeted funding initiatives are fortifying laboratory networks and expanding access to diagnostics in underserved regions.

Asia-Pacific exhibits the highest growth trajectory, driven by medical infrastructure expansion in China, India, Southeast Asian nations, and Australia. Local manufacturing hubs are scaling up production of reagents and instruments, and governments are prioritizing genomic surveillance programs. The combination of cost competitiveness and rising clinical demand positions the region as both a manufacturing powerhouse and a rapidly expanding consumer of high-end diagnostic solutions.

Strategic Moves Shaping Competitive Dynamics

Leading diagnostic companies are sharpening their focus on integrated solutions that span instrument platforms, assay kits, software analytics, and service offerings. Major firms are channeling R&D investments into next-generation sequencing panels and high-throughput polymerase chain reaction systems, while simultaneously diversifying into point-of-care immunoassay and molecular units. Collaborations between instrument manufacturers and reagent suppliers are accelerating the co-development of system-validated consumables, ensuring optimal performance and customer loyalty.

Strategic partnerships with biotechnology firms and academic centers are fostering innovation in novel biomarker discovery and assay development. Several prominent players have pursued acquisitions of specialized start-ups to expand their molecular and digital capabilities. Meanwhile, mid-tier companies are capitalizing on niche markets by offering modular platforms that enable seamless integration into existing laboratory workflows. Collectively, these competitive dynamics emphasize a shift toward comprehensive service models paired with outcome-driven engagement strategies.

Prioritizing Integration, Innovation, and Collaborative Growth

Industry leaders should prioritize investment in flexible manufacturing footprints to offset tariff-related cost pressures and ensure uninterrupted supply. Expanding collaborations across the ecosystem-encompassing reagent collectors, instrument integrators, informatics specialists, and regulatory consultants-will be critical to accelerate innovation and reduce time to market. Embracing digital connectivity, from instrument-embedded artificial intelligence to cloud-based data analytics, will enrich product value propositions and foster deeper customer relationships.

Advancing point-of-care testing solutions tailored to emerging outbreak scenarios can drive market differentiation, while strategic engagement with policymakers on reimbursement pathways and regulatory frameworks will safeguard long-term access. Building on core diagnostic strengths, companies should explore adjacent opportunities in antimicrobial resistance profiling and pathogen genomics. By integrating outcome-based contracting and service-oriented delivery models, organizations can enhance revenue predictability and align incentives with patient-centric performance metrics.

Methodical Approach Anchored in Multisource Validation

This research synthesizes insights drawn from an extensive review of peer-reviewed literature, regulatory filings, company financial disclosures, and industry trade resources. Primary data collection involved structured interviews with senior executives from leading diagnostic firms, laboratory directors, key opinion leaders in infectious disease research, and procurement specialists from major healthcare systems. A rigorous data triangulation process ensured that qualitative perspectives aligned with quantitative indicators, while market segmentation by test type, technology, pathogen class, end user, and application provided a multi-dimensional view of the landscape.

Regional analyses were underpinned by national health statistics, import-export data, and localized expert consultations. The methodological framework incorporated competitive benchmarking, patent landscaping, and scenario modeling to evaluate tariff impacts and innovation trajectories. Findings were validated through peer review and stakeholder workshops to confirm accuracy and relevance. This robust approach delivers a dependable foundation for strategic decision-making across the infectious diseases in-vitro diagnostics domain.

Synthesizing Insights to Forge a Resilient Future

The infectious diseases in-vitro diagnostics market stands at a pivotal juncture, where scientific breakthroughs converge with geopolitical shifts and evolving healthcare priorities. Market participants who adapt with agility, foster cross-sector collaborations, and harness digital transformation will secure leadership in both established and emerging segments. Innovations in molecular assays, rapid tests, and integrated informatics promise to enhance patient outcomes while delivering critical public health intelligence.

While tariff pressures introduce short-term cost complexities, they also catalyze supply chain optimization and manufacturing agility. Strategic alignment with regulatory bodies and payers will be indispensable for unlocking broader market access. By leveraging comprehensive segmentation insights and regional growth imperatives, companies can tailor their strategies to local demands and global trends. The path forward demands a balanced pursuit of innovation, operational excellence, and value-based engagement to chart sustained success in this fast-evolving arena.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Test Type
    • Culture Tests
      • Automated Culture
      • Manual Culture
    • Molecular Diagnostics
      • Loop Mediated Isothermal Amplification
      • Next Generation Sequencing
      • Polymerase Chain Reaction
    • Rapid Tests
    • Serology Tests
      • Chemiluminescence Immunoassay
      • Enzyme Linked Immunosorbent Assay
      • Lateral Flow Assay
  • Technology
    • Immunoassay
    • Mass Spectrometry
    • Microarray
    • Polymerase Chain Reaction
    • Sequencing
  • Pathogen
    • Bacterial
      • Enterobacteriaceae
      • Mycobacterium Tuberculosis
      • Staphylococcus Aureus
    • Fungal
    • Parasitic
    • Viral
      • Hepatitis Virus
      • Human Immunodeficiency Virus
      • Influenza Virus
  • End User
    • Academic Research Institution
    • Clinic
    • Hospital
      • Private Hospital
      • Public Hospital
    • Laboratory
      • Clinical Laboratory
      • Reference Laboratory
  • Application
    • Diagnosis
    • Epidemiological Surveillance
    • Monitoring
    • Screening
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • bioMérieux SA
  • Siemens Healthineers AG
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Becton Dickinson and Company
  • Qiagen N.V.
  • Hologic, Inc.
  • Bio-Rad Laboratories, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Infectious Diseases in-Vitro Diagnostics Market, by Test Type
8.1. Introduction
8.2. Culture Tests
8.2.1. Automated Culture
8.2.2. Manual Culture
8.3. Molecular Diagnostics
8.3.1. Loop Mediated Isothermal Amplification
8.3.2. Next Generation Sequencing
8.3.3. Polymerase Chain Reaction
8.4. Rapid Tests
8.5. Serology Tests
8.5.1. Chemiluminescence Immunoassay
8.5.2. Enzyme Linked Immunosorbent Assay
8.5.3. Lateral Flow Assay
9. Infectious Diseases in-Vitro Diagnostics Market, by Technology
9.1. Introduction
9.2. Immunoassay
9.3. Mass Spectrometry
9.4. Microarray
9.5. Polymerase Chain Reaction
9.6. Sequencing
10. Infectious Diseases in-Vitro Diagnostics Market, by Pathogen
10.1. Introduction
10.2. Bacterial
10.2.1. Enterobacteriaceae
10.2.2. Mycobacterium Tuberculosis
10.2.3. Staphylococcus Aureus
10.3. Fungal
10.4. Parasitic
10.5. Viral
10.5.1. Hepatitis Virus
10.5.2. Human Immunodeficiency Virus
10.5.3. Influenza Virus
11. Infectious Diseases in-Vitro Diagnostics Market, by End User
11.1. Introduction
11.2. Academic Research Institution
11.3. Clinic
11.4. Hospital
11.4.1. Private Hospital
11.4.2. Public Hospital
11.5. Laboratory
11.5.1. Clinical Laboratory
11.5.2. Reference Laboratory
12. Infectious Diseases in-Vitro Diagnostics Market, by Application
12.1. Introduction
12.2. Diagnosis
12.3. Epidemiological Surveillance
12.4. Monitoring
12.5. Screening
13. Americas Infectious Diseases in-Vitro Diagnostics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Infectious Diseases in-Vitro Diagnostics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Infectious Diseases in-Vitro Diagnostics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. Abbott Laboratories
16.3.3. bioMérieux SA
16.3.4. Siemens Healthineers AG
16.3.5. Danaher Corporation
16.3.6. Thermo Fisher Scientific Inc.
16.3.7. Becton Dickinson and Company
16.3.8. Qiagen N.V.
16.3.9. Hologic, Inc.
16.3.10. Bio-Rad Laboratories, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET MULTI-CURRENCY
FIGURE 2. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET MULTI-LANGUAGE
FIGURE 3. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2024 VS 2030 (%)
FIGURE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MANUAL CULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENTEROBACTERIACEAE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MYCOBACTERIUM TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 83. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 84. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 85. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 86. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 87. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 89. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 90. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 91. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 93. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 94. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 96. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 97. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 99. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 100. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 101. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 102. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 103. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 105. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 106. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 156. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 157. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 158. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 159. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 160. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 162. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 163. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 164. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 166. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 167. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 169. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 170. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 171. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 172. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 173. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 174. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 175. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 176. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 178. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 179. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 192. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 193. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 194. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 195. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 196. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 198. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 199. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 200. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 202. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 203. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 204. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 205. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 206. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 207. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 208. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 209. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 210. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 211. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 212. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 214. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 215. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 248. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 250. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 253. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 254. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 255. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 256. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 258. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 259. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 260. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 262. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 263. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 269. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 270. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 271. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 272. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 274. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 275. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 276. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 277. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CULTURE TESTS, 2018-2030 (USD MILLION)
TABLE 278. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 279. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 280. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 281. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 282. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET

Companies Mentioned

The companies profiled in this Infectious Diseases In-Vitro Diagnostics market report include:
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • bioMérieux SA
  • Siemens Healthineers AG
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Becton Dickinson and Company
  • Qiagen N.V.
  • Hologic, Inc.
  • Bio-Rad Laboratories, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages186
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 56.4 Billion
Forecasted Market Value ( USD ) by 2030 $ 80 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Infectious Disease In Vitro Diagnostics Market Size, Share & Trends Analysis Report by Product (Instruments, Reagents, Software), Technology, Application, Test Location, Region, and Segment Forecasts, 2024-2030 - Product Image

Infectious Disease In Vitro Diagnostics Market Size, Share & Trends Analysis Report by Product (Instruments, Reagents, Software), Technology, Application, Test Location, Region, and Segment Forecasts, 2024-2030

  • Report
  • 190 Pages
  • Global
From
Infectious Disease In-Vitro Diagnostic Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2025-2032 - (By Product Type, Technology, End User, Geographic Coverage and By Company) - Product Image

Infectious Disease In-Vitro Diagnostic Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2025-2032 - (By Product Type, Technology, End User, Geographic Coverage and By Company)

  • Report
  • 193 Pages
  • Global
From
In-Vitro Diagnostics Instrument Market by Instrument Type, Application, Technology, End User, Configuration - Global Forecast to 2030 - Product Image

In-Vitro Diagnostics Instrument Market by Instrument Type, Application, Technology, End User, Configuration - Global Forecast to 2030

  • Report
  • 195 Pages
  • Global
From
In-vitro Diagnostics Enzymes Market Size, Share & Trends Analysis Report By Enzyme, By Disease, By Technology, By End-use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

In-vitro Diagnostics Enzymes Market Size, Share & Trends Analysis Report By Enzyme, By Disease, By Technology, By End-use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
In-Vitro Diagnostics Market by Product Type (Instruments, Reagents & Kits, Services), Test Type (Clinical Chemistry, Hematology, Immunoassays), Specimen, Application, End User - Global Forecast 2025-2030 - Product Image

In-Vitro Diagnostics Market by Product Type (Instruments, Reagents & Kits, Services), Test Type (Clinical Chemistry, Hematology, Immunoassays), Specimen, Application, End User - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From

About the IVD Infectious Disease Market

The In Vitro Diagnostics (IVD) Infectious Disease market is a segment of the larger IVD industry that focuses on the diagnosis and monitoring of infectious diseases. It includes a range of products and services, such as tests for the detection of bacteria, viruses, fungi, and parasites, as well as tests for the identification of drug-resistant organisms. These tests are used to diagnose and monitor the progression of infectious diseases, as well as to guide treatment decisions. The IVD Infectious Disease market is driven by the increasing prevalence of infectious diseases, the emergence of new and drug-resistant pathogens, and the need for rapid and accurate diagnosis. Additionally, technological advances in molecular diagnostics, such as PCR and next-generation sequencing, have enabled the development of more sensitive and specific tests. Notable companies in the IVD Infectious Disease market include Abbott, Becton Dickinson, Roche, Siemens Healthineers, and Thermo Fisher Scientific. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.